Physician profile
Daniel Camarillo
NPI 1073693552
$3,086.17
in general payments reported to CMS, 2019-2025
31 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $110 · 2021: $317 · 2022: $754 · 2023: $657 · 2024: $662 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $357.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $355.70 | 2021-2025 | Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.62 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $251.51 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $226.32 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Antares Pharma, INC. | $193.57 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $181.43 | 2021-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $160.00 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $143.59 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $127.47 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $86.38 | 2022-2023 | Belsomra, Verquvo, Steglatro |
| Xeris Pharmaceuticals, INC. | $67.44 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $66.80 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $58.32 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $55.29 | 2019-2023 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $52.57 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $48.10 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $44.72 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $41.70 | 2024-2025 | Tlando |
| Kowa Pharmaceuticals America, INC. | $35.85 | 2023-2024 | Livalo, Seglentis |
| Lundbeck LLC | $33.04 | 2025 | Rexulti |
| Allergan, INC. | $31.35 | 2020 | |
| Smith+Nephew, INC. | $31.21 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $29.70 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $26.73 | 2021 | |
| Astellas Pharma US INC | $26.30 | 2024 | Veozah |
| Medtronic, INC. | $20.22 | 2025 | Venaseal |
| Novartis Pharmaceuticals Corporation | $16.89 | 2023 | |
| Currax Pharmaceuticals LLC | $15.99 | 2025 | Contrave |
| Eisai INC. | $15.40 | 2021 | |
| Amarin Pharma, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Camarillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.